Short answer
Maze Therapeutics, Inc. (MAZE) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$30M
- +10.7% QoQ
- EPS (diluted)
- −$0.62
- +8.8% QoQ
Source: XBRL data from the Maze Therapeutics, Inc. (MAZE) Q3 2025 10-Q on SEC EDGAR. USD.
Maze Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Phase 2 trial of MZE829 initiated Nov 2024; topline proof of concept data expected Q1 2026, triggered by recent clinical progress
- Material update: Net loss $96.6M 9M 2025 vs net income $81.8M 9M 2024; accumulated deficit $455.0M due to increased R&D and operational costs
- Regulatory risk: Potential FDA-imposed requirements for additional preclinical or clinical studies may materially increase expenses and delay approvals
- Market risk: Dependence on timely patient enrollment and trial completion for MZE829 and MZE782 impacts near-term clinical milestones and development timelines
- Financial risk: Cash, equivalents, and securities $383.9M as of Sept 30, 2025, sufficient for at least one year of operations but additional capital needed thereafter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Maze Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.